Bharat Biotech gets DGCI nod for intranasal Covid booster doses

0 158

The Drugs Controller General of India (DCGI) on Friday gave its permission to Bharat Biotech for conducting trials of intranasal booster doses against the coronavirus disease (Covid-19).

According to an input from news agency ANI, the trials will be held at nice different sites.

A day ago, the Hyderabad-based pharmaceutical company’s anti-Covid vaccine Covaxin was recently granted regular market approval for use in the adult population subject to certain conditions along with Serum Institute of India’s Covishield.

Leave A Reply

Your email address will not be published.